
	AUG 112	2005	نه 11ز	·		SN/35/05/QB
Substitute for form 1448 OF TRADEMANA				Complete if Known		
				Application Number	10/519,505	
INFO	RMATION D	ISC	CLOSURE	Filing Date	June 27, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Bjorn NEXO	
				Group Art Unit		
	(use as many sheets	as n	ecessary)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	NEXO1	·····

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/STK/	AA		12-03-1996	VOGELSTEIN	
	AB	US- 6,005,088	12-21-1999	FUJIWARA et al	
	AC	US- 6,084,088	07-04-2000	SHEPPARD et al	
	AD	US- 6,235,280	05-22-2001	CHATTERJEE et al	
	AE	US- 2002/0022591	02-21-2002	ALGATE et al	·
	AF	US- 2002/0028460	03-07-2002	PINKEL et al	
$\nabla$	AG	US- 2002/0040127	04-04-2002	JIANG et al	
	AH	US- 6,406,891	06-18-2002	LEGERSKI	
		US-			

		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Number  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
/STK	Al	CA 2,116,633	08-29-1995	JOUTEL et al		
	AJ	CA 2,116,628	08-29-1995	JOUTEL et al		
	AK	WO 95/16791	06-22-1995	POIRIER, J		
	AL	WO 96/32956	10-24-1996	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA		
•	AM	WO 01/27265	04-19-2001	UNIVERSITAT BREMEN		
	AN	WO 01/47957	07-05-2001	01 ZYMOGENETICS, INC.		
	AO	WO 02/02627	01-10-2002	ZYMOGENETICS, INC.		
	AP	WO 02/29107	04-11-2002	BOARD OF REGENTS		
	AQ	WO 02/057489	07-25-2002	RESPONSE GENETICS, INC.		_
	AR	WO 02/061128	08-08-2002 RESPONSE GENETICS, INC.			
	AS	WO 02/100248	12-19-2002	BOARD OF REGENTS		
	AT	WO 03/004640	01-16-2003	TAIHO PHARMACEUTICAL CO. LTD		
	AU	WO 03/008643	01-30-2003	CANCER RESEARCH TECHNOLOGY LIMITED		
W	AV	EP 1 146 054	10-17-2001	ONO PHARMACEUTICAL CO. LTD.		

Examiner Signature	/Stephen Kapushoc/	Date Considered	07/28/2007

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nationally in the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.



		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
/STK/ AW		A.M. Brewster et al., "THE ASSOCIATION BETWEEN POLYMORPHISMS IN THE XERODERMA PIGMENTOSUM GROUP D GENE AND RISK OF BREAST CANCER" American Journal of Epidemiology, vol. 153, no. 11, (2001), p. S198 "Abstract"					
$\cdot \mid$	AX	Bergamaschi et al., :IASPP oncoprotein is a key inhibitor of p53 conserved from worm to human* Nature Genetics, vol. 33, (2003), pp. 162-167					
	AY	Bjørn Nexø et al. "A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55." Carcinogenesis, vol. 24, no. 5, (2003), pp. 899-904					
	AZ	Dorota Butkiewicz et al. "Genetic Polymorphisms in DNA repair genes and risk of lung cancer." Carcinogenesis, vol. 22, no. 4, (2001) pp:593-597					
	ВА	Eszter Rockenbauer et al. Association of chromosome 19q13.2-3 haptotypes with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts. Carcinogenesis, vol. 23, no. 7, (2002), pp. 1149-1153					
	BB	Jing Jie Yu et al. "AN ERCC1 SPLICING VARIANT INVOLVING THE 5'-UTR OF THE MRNA MAY HAVE A TRANSCRIPTIONAL MODULATORY FUNCTION" ONCOGENE (2001) 20. pp: 7694-7698.					
	ВС	Marianne Dybdahl et al. "POLYMORPHISMS IN THE DNA REPAIR GENE XPD: CORRELATIONS WITH RISK AND AGE AT ONSET OF BASAL CELL CARCINOMA". CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION VOL. 8, (JANUARY 1999) pp: 77-81,					
	BD	Pengchin Chen et al. "Association of en ERCC1 Polymorphism with Adult-Onset Glioma." Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 8, (2000), pp. 843-847					
	BE	Richard Shen et al. "Nonconservative Amino Acid Substitution Variants Exist at Polymorphic Frequency in DNA Repair Genes in Healthy Humans." Cancer Research, vol. 58, no. 4, (1998), pp. 604-608					
	BF	Ulla Vogel et al. "POLYMORPHISMS OF THE DNA REPAIR GENE XPD: CORRELATIONS WITH RISK OF BASAL CELL CARCINOMA REVISITED." CARCINOGENESIS VOL.22 NO. 6 (2001) pp. 899-904.					
	BG	Ulia Vogel et al. "DNA REPAIR CAPACITY: INCONSISTENCY BETWEEN EFFECT OF OVER-EXPRESSION OF FIVE NER GENES AND THE CORRELATION TO MRNA LEVELS IN PRIMARY LYMPHOCYTES." MUTATION RESEARCH 461 (2000) pp: 197-210.					
	вн	Yang Jian-Ping et al. "Identification of a Novel Inhibitor of Nuclear Factor-xB, Re1A-associated Inhibitor." J. Biol. Chem., vol. 274, no. 22, (1999), pp. 15662-15670					
	ВІ	Yin Jiaoyang et al.: "Multiple Single Nucleotide Polymorphisms of Human Chromosome 19q13.2-3 Associate with Risk of Basal Cell Carcinoma." Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 11, (2002), pp. 1449-1453					
V	BJ	Yin Jiaoyang et al. "Twelve Single Nucleotide Polymorphisms on Chromosome 19q13.2-3-13.3: Linkage Disequilibria and Associations with Basal Cell Carcinoma in Danish Psoriatic Patients." Biochemical Genetics, vol. 41, no. 1-2, (2003), pp: 27-37					

Examiner Signature /Stephen Kapushoc/	Date Considered	07/28/2007
---------------------------------------	--------------------	------------

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.